PRISMA Maternal & Newborn Health Study

Status Recruiting

Clinical Trial Summary

Access to quality antenatal care (ANC) and postnatal care (PNC), including maternal, newborn, and infant services, is integral to reducing adverse pregnancy-related health outcomes and promoting positive birth experiences. The World Health Organization (WHO) recommends a total of eight ANC visits for pregnant women. However, the ANC coverage rate remains considerably lower among more vulnerable populations, and the quality of care that women receive is inconsistent, often poor, and frequently fails to detect risks in a timely fashion or adequately prepare women for the birth process. While rates of facility-based delivery are on the rise worldwide, disparities persist and the quality of care across facilities remains uneven. Even less information is available on PNC, where services beyond routine immunizations may not be widely available, especially in resource-poor regions. Additionally, limited evidence exists on innovative service delivery approaches and how to effectively scale tested maternal and newborn health (MNH) interventions. This coupled with the fragmented datasets from smaller studies limit our ability to advocate for policy change. The Pregnancy Risk Stratification Innovation and Measurement Alliance (PRiSMA) is implementing a harmonized open cohort study that seeks to evaluate pregnancy risk factors and their associations with adverse pregnancy outcomes, including stillbirth, neonatal mortality and morbidity, and maternal mortality and severe morbidity. The goals are to develop a harmonized data set to improve understanding of pregnancy risk factors, vulnerabilities, and morbidity and mortality and to estimate the burden of these risk factors and outcomes in LMICs. Ultimately, these data will inform development of innovative strategies to optimize pregnancy outcomes for mothers and their newborns.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Pregnancy, High Risk

Clinical Trial Details

NCT number	NCT05904145
Study type	Observational
Source	George Washington University
Contact	Emily R Smith, ScD, MPH
Phone	12029943589
Email	emilysmith@gwu.edu
Status	Recruiting
Phase
Start date	August 1, 2022
Completion date	February 28, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03651843` - Perception of Risks Into Work During Pregnancy Among Post-partum Women in the Lille Metropolis
Active, not recruiting	`NCT05656352` - Validation of a Non-invasive Hemoglobin Measurement Device in Pregnancy and Postpartum in Kenya, Pakistan, and Zambia
Not yet recruiting	`NCT06430853` - Psychobiological Interventions in Pregnancy	N/A
Completed	`NCT05316415` - The Effects of Music on the Anxiety and Sleep Quality of Pregnant Women on Bed Rest for a High-risk Pregnancy	N/A
Not yet recruiting	`NCT03985618` - The MODE Trial: Planned Caesarean Section Versus Induction of Labour for Women With Class III Obesity	N/A
Completed	`NCT02008097` - Clinical Benefits of B-Flow Ultrasound	N/A
Recruiting	`NCT05922033` - Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER)	Phase 4
Completed	`NCT03413631` - A Prenatal Mentalization-focused 4D Ultrasound and a Pregnancy Diary Intervention for Substance-abusing Women	N/A
Not yet recruiting	`NCT05388643` - Early Detection of Gestational Diabetes Mellitus in Pregnancy	N/A
Not yet recruiting	`NCT05317585` - Continuous Glucose Monitor Use in Pregnancy	N/A
Recruiting	`NCT04861103` - Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)	Phase 4
Completed	`NCT03334149` - Blood Pressure Monitoring in High Risk Pregnancy to Improve the Detection and Monitoring of Hypertension	N/A
Completed	`NCT03646487` - A Randomized Placebo Controlled Pilot Study of Probiotic Supplementation in At-risk Pregnant Women	N/A
Recruiting	`NCT05198206` - Pregnant Women With Pulmonary Hypertension in China
Recruiting	`NCT05739123` - Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
Recruiting	`NCT05807256` - Medically Assisted Fertilization Techniques in Systemic Immunoreumatologic Diseases
Completed	`NCT04874285` - Use of Dietary Supplements in Patients at Risk of Abortion Treated With Progesterone.	N/A
Not yet recruiting	`NCT05662462` - Successfully Achieving and Maintaining Euglycemia During Pregnancy for Type 2 Diabetes Through Technology and Coaching	N/A
Recruiting	`NCT03975894` - TAPS2 Transfusion Antenatally in Pregnant Women With SCD	Phase 2
Recruiting	`NCT05597943` - mHealth Smartphone App and Postpartum Glucose Intolerance for Patients With GDM	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

PRISMA Maternal and Newborn Health Study — PRiSMA-MNH

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms